The Tripp study will extend the approved use to patients on folfirinox which is the commonest chemo used in pancreatic ca. So that will increase eligibility.
It will also add to the effectiveness dossier for government reimbursement because it’s an RCT so the prospect of public funding becomes much more likely.
This is the study the company should have done 10 years ago.
Gets the product being used in hospitals which irons out process, leads to word of mouth, case presentations etc
Also some patients randomised to placebo might pull out and pay.
The Tripp study will extend the approved use to patients on...
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.001(4.00%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.4¢ | 1.2¢ | $176.4K | 13.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 5353143 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 493343 | 1 |
View Market Depth
| Last trade - 15.45pm 13/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |